EQS-News

Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES 06.12.2022 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement.

_________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE

 

 

DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOX^TM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES

 

Vancouver, BC, Canada, December 6^th, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOX^TM molecule. The company is planning to meet with the FDA in the weeks to come to obtain approval for launching its Phase I trial against solid tumors.     

 

AccuTOX^TM: a fierce anti-cancer treatment.

In the past 16 months, Defence engineered a large library of Accum^TM variants exhibiting differential effects on both immune and cancer cells. One of these lead molecules is AccuTOX^TM, a small compound capable of effectively killing a large set of murine and human tumors by inducing the production of reactive oxygen species, causing immunogenic cells death as well as triggering direct DNA damage akin to chemotherapeutic agents. Interestingly, AccuTOX^TM administration synergises with different immune-checkpoints (anti-PD-1, anti-CTLA4 and anti-CD47) making it a highly mouldable molecule adaptable to a myriad of solid cancer indications. For instance, AccuTOX^TM dosed at 16 mg/kg halts the growth of solid T-cell lymphoma, melanoma as well as breast cancer in mice with a survival rate of more than 90%. These results combined to the molecular characterization of AccuTOX^TM’s mechanism of action clearly highlight the anti-neoplastic potential of this molecule as a next generation treatment for various cancer types.